Royalty Pharma(RPRX)

Search documents
Royalty Pharma Reports First Quarter 2025 Results
GlobeNewswire· 2025-05-08 11:15
Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12%Net cash provided by operating activities of $596 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $2,975 to $3,125 million NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts. “Our business momentum continued in the first quarter of 2025 as we delivered double- ...
Unlocking Q1 Potential of Royalty Pharma (RPRX): Exploring Wall Street Estimates for Key Metrics
ZACKS· 2025-05-05 14:21
Wall Street analysts expect Royalty Pharma (RPRX) to post quarterly earnings of $0.99 per share in its upcoming report, which indicates a year-over-year increase of 1%. Revenues are expected to be $793.58 million, up 10.7% from the year-ago quarter.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Prior to a company's earnings release, i ...
Royalty Pharma Declares Second Quarter 2025 Dividend
GlobeNewswire· 2025-04-21 20:15
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collabor ...
Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025
GlobeNewswire· 2025-04-17 20:15
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view th ...
Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors
GlobeNewswire News Room· 2025-04-08 20:15
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. “I am excited to announce that we are strengthening our Board w ...
Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors
Newsfilter· 2025-04-08 20:15
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Vlad Coric, M.D. to the company's Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. "I am excited to announce that we are strengthening our Board wi ...
Royalty Pharma Announces Upcoming Investor Day
GlobeNewswire· 2025-03-27 12:15
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m. ET. Royalty Pharma senior executives will provide an update on the company’s plans to drive shareholder value creation through leveraging its unique business model and capabilities in the large and growing market for funding biopharma innovation. The meeting will include live question and answer sessions. Addi ...
Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference
GlobeNewswire· 2025-02-27 21:15
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on March 4, 2025 at 2:30 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties an ...
Royalty Pharma: Delivering Growth With A Positive Story Ahead
Seeking Alpha· 2025-02-13 03:02
Following our recent update on Royalty Pharma plc (NASDAQ: RPRX ) - Key Strategic Updates To Be Priced In , we are back to comment on the company's quarterly results. Since our strong buy recommendation released in earlyBuy-side hedge professionals conducting fundamental, income oriented, long term analysis across sectors globally in developed markets. Please shoot us a message or leave a comment to discuss ideas.DISCLOSURE: All of our articles are a matter of opinion, informed as they might be, and must be ...
Royalty Pharma(RPRX) - 2024 Q4 - Annual Report
2025-02-12 14:20
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ 110 East 59 Street th New York, New York 10022 (Address of principal executive offices and Zip Code) (212) 883-0200 (Registrant's telephone ...